Navigation Links
Kosan Presents Promising Phase 1 Data on Second-Generation Hsp90,Inhibitor, Alvespimycin, Showing Antitumor Activity in Refractory,Breast and Ovarian Cancers at ASCO

Clinical Benefit Shown in 35% of HER2-Positive Metastatic Breast Cancer Patients

HAYWARD, Calif., June 04, 2007 /PRNewswire-FirstCall/ -- Kosan Biosciences Incorporated presented data from a Phase 1 clinical trial showing that alvespimycin, its second-generation Hsp90 inhibitor, demonstrated promising antitumor activity and tolerability in combination with trastuzumab (Herceptin(R)) in patients with refractory HER2-positive metastatic breast cancer, and in patients with refractory ovarian cancer who were progressing on standard chemotherapy. Data from the ongoing trial in patients with solid tumors were presented on Saturday, June 2, 2007, by Kathy Miller, M.D., Indiana University, Indianapolis, IN, in a poster, titled, "Phase 1 Trial of Alvespimycin (KOS-1022; 17-DMAG) and Trastuzumab," at the 2007 Annual Meeting of the American Society of Clinical Oncology (ASCO).

"Alvespimycin's antitumor activity is interesting given the highly refractory stage of disease of the patients in this Phase 1 trial and the drug's mechanism of action," said Clifford A. Hudis, M.D., Chief of the Breast Cancer Service, Memorial Sloan-Kettering Cancer Center, and the study's senior author. "Alvespimycin's potential to work additively or synergistically with standard chemotherapy agents suggests that it could be an important addition to the treatment paradigm for HER2-positive metastatic breast cancer."

"These encouraging Phase 1 data support our strategy to pursue alvespimycin as a potential treatment for HER2-positive metastatic breast cancer and to advance into Phase 2 trials later this year," said Robert G. Johnson, Jr., M.D., Ph.D., Kosan's President and Chief Executive Officer. "Kosan has the unique advantage of having two promising Hsp90 inhibitors, tanespimycin and alvespimycin, in clinical development at the same time. Both of these compounds are showing meaningful clinical benefit and a high degree of tolerabil
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Kosan Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Epothilone KOS-1584 at ASCO
2. Kosan Presents Data on Lead Hsp90 Inhibitor, Tanespimycin, Showing Promising Antitumor Activity in Multiple Myeloma at ASCO
3. Kosan Presents Preliminary Phase 2 Data Showing Antitumor Activity of Hsp90 Inhibitor Tanespimycin in Metastatic Melanoma at ASCO
4. Kosan Presents Preclinical Data on Nuclear Export Inhibitors, Novel Anticancer Agents, at AACR
5. Kosan Presents Preclinical Antitumor and Safety Data On Next-Generation Epothilone KOS-1803 at AACR
6. Kosan Presents Data on Cardiac Safety Profile of Hsp90 Inhibitor Tanespimycin (KOS-953) at AACR
7. Kosan Announces Data Presentations at Upcoming AACR Annual Meeting
8. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
9. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
10. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
11. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
Post Your Comments:
(Date:12/24/2014)... , Dec. 24, 2014 /CNW/ - ... being recalled after Health Canada tests confirmed it contains ... risks (beta-methylphenethylamine and phenylpropylmethylamine). The distributor, Empire Health Distribution ... the product from retail stores across Canada ... purposes, including for weight loss and increased energy. ...
(Date:12/24/2014)... Dec. 24, 2014 /PRNewswire/  -- Tianyin Pharmaceutical Inc. ... company that specializes in the patented biopharmaceutical, modernized ... pharmaceutical ingredients (API) released unaudited preliminary financial results ... Fiscal Year 2015 Ended September 30, ... million compared with $14.7 million in 1Q14 with ...
(Date:12/24/2014)... 2014  Conkwest, Inc., the Natural Killer Cell ... Killer (NK) cell-line platform, Neukoplast® (NK-92™) as an ... , NantWorks founder, physician scientist and biotechnology entrepreneur, ... approximately $48 million of the Company,s Class A ... will be named Co-Chairman of the Conkwest Board ...
Breaking Medicine Technology:"Jetfuel Superburn" recalled after Health Canada tests find undeclared drug ingredients 2TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 2TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 3TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 4TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 5TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 6TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 7TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 8TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 9TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 10TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 11TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 12Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 2Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 3Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 4Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 5
... DIEGO, Aug. 3, 2011 Proacta Incorporated and ... the expansion of their Collaborative Research, Development and ... a hypoxia-activated pro-drug for the treatment of cancer. ... parties agreed to expand their existing collaboration to ...
... Buehler Motor, Inc. ( http://www.buehlermotor.com ), a global ... challenging mechatronic drive solutions, today announced a partnership with ... of its DC/BLDC motor and gearmotor lines. ... South American medical equipment market, and introduce a new ...
Cached Medicine Technology:Proacta Incorporated and Yakult Honsha Announce Expansion of Their Collaborative Research, Development and Commercialization Agreement 2Proacta Incorporated and Yakult Honsha Announce Expansion of Their Collaborative Research, Development and Commercialization Agreement 3Buehler Motor Establishes Sales Partner in Brazil 2Buehler Motor Establishes Sales Partner in Brazil 3
(Date:12/25/2014)... 26, 2014 The microscopy market ... 7.2% to reach $5,756.0 million by 2019. Optical ... market. The electron microscopes product segment is expected ... period. , Rising focus on nanotechnology, technological advancements, ... the microscopy market. , Get Full Copy of ...
(Date:12/25/2014)... Dallas, TX (PRWEB) December 26, 2014 ... and Market Analysis to 2023” focuses on the ... commercial opportunities in the colorectal cancer market. Stivarga ... treatment of colon or rectal cancer. Boehringer Ingelheim ... inhibitor, for the treatment of refractory CRC in ...
(Date:12/25/2014)... “Every three months the trends for evening ... dress will be one of the hottest styles in the ... Today, the company releases 26 A-line sweetheart evening dresses, and ... , “We are trying our best to help a ... designs. Along with affordable prices, we provide discounted delivery costs ...
(Date:12/25/2014)... December 25, 2014 The short film “Color ... created in honor of a true 9/11 hero, Welles Remy ... festivals including the 24 hours of Nuremberg International Short Film ... , Actress, screenwriter and director Luciana Lagana ... film together with her husband, Gregory Graham - ...
(Date:12/25/2014)... 2014 Helen Harris’ RP (Retinitis Pigmentosa) ... California after an 8 year battle with breast cancer. ... evening in her home in Woodland Hills California after ... , As the founder and volunteer ... pioneered and championed many of today's greatest breakthroughs in ...
Breaking Medicine News(10 mins):Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 2Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 3Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 4Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 4Health News:The True 9/11 Hero Story “Color of Honor” Premieres in Germany and Bangladesh: Luciana Lagana Plays the Mother of the Lead and Co-Produces with Blaise Dolcemaschio. 2Health News:The True 9/11 Hero Story “Color of Honor” Premieres in Germany and Bangladesh: Luciana Lagana Plays the Mother of the Lead and Co-Produces with Blaise Dolcemaschio. 3Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 2Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 3Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 4
... Feb. 9 (HealthDay News) -- A growing number of Americans ... social networking sites rather than friends, a new survey ... information from social media such as Facebook and Twitter, a ... number of patients who sought information from friends fell from ...
... Moffitt Cancer Center in Tampa, Fla., have discovered that ... roles in tobacco-related non-small cell lung cancers. Tobacco carcinogens ... The study was published in a recent issue ... identified oconogene, a gene linked to cancer," said study ...
... certain cancer cells may exhibit greater flexibility than normal ... tumor growth. Now computer simulations developed by Boston University ... the University of Texas at Austin appear to support ... cells that they,ve created indicates that the softening of ...
... 9, 2012) In a study to be presented ... The Pregnancy Meeting , in Dallas, Texas, researchers will ... delivery via cesarean section appear to know little about ... second cesarean or trial of labor to attempt a ...
... Fla. and ORLANDO, Fla. Moffitt Cancer Center, ... announced they will collaborate on the creation of ... The partnership will conduct collaborative research to accelerate ... of cancer and metabolic diseases, including obesity, diabetes ...
... SAN FRANCISCO There is growing evidence that supports an association ... the thigh bone, typically without trauma and the use ... fracture incidence caused by osteoporosis. While the risk for suffering ... small just 1 in 1,000 patients after six years ...
Cached Medicine News:Health News:More Patients Seek Plastic Surgery Advice From Facebook, Twitter 2Health News:Researchers find important 'target' playing role in tobacco-related lung cancers 2Health News:Boston University research suggests new pathways for cancer progression 2Health News:Study finds pregnant women with prior cesarean choose the delivery method preferred by their doctor 2Health News:Moffitt, Sanford-Burnham and Florida Hospital create Personalized Medicine Partnership of Florida 2Health News:Moffitt, Sanford-Burnham and Florida Hospital create Personalized Medicine Partnership of Florida 3Health News:Halting bone-building osteoporosis drug use cuts risk for additional atypical femur fracture in half 2
Compact networked patient monitors for flexible care....
... heritage in patient monitoring, IntelliVue has highly ... menu; built-in clinical support tools such as ... arrhythmia analysis; and many other powerful features., ... operates on a networked platform that can ...
... vital sign monitor. , ,Adult, pediatric, and neonatal. ... in patient care., ,Standard Functions: ,ECG - Respiration ... Multi-gas Sensor (HAL, ENF, ISO, DES, SEV, N ... ECG - FiO 2 - 2-Invasive Pressures - ...
... Welch Allyn Atlas monitor is a low-cost, ... IV anesthesia procedures, and surgery. The large ... that are visible from across the room. ... how to operate the monitor in just ...
Medicine Products: